Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
|Articles|June 15, 2019
- BioPharm International-06-15-2019
- Volume 2019 eBook
- Issue 2
New Strategies for Managing Single-Use Components
Author(s)Timothy Korwan, Jay Harp
Dual-sourcing and redundant manufacturing capabilities are crucial in a single-use supply chain strategy, but must be applied correctly.
Advertisement
As single-use systems (SUS) have increasingly been implemented in GMP biopharmaceutical production, supply-chain assurance for SUS materials, components, and assemblies has become even more important. Dual-sourcing and redundant manufacturing capabilities are crucial in a single-use supply chain strategy. However, these tenets of supply-chain management are often misapplied and undervalued, leading to potential risk that can result in delays or even stoppages in critical drug production.
Read
Article Details
BioPharm International
eBook: Single-Use Systems
Vol. 32
June 2019
Pages: 10–13
Citation
When referring to this article, please cite it as T. Korwan and J. Harp, " New Strategies for Managing Single-Use Components," BioPharm International Single-Use Systems eBook (June 2019).
Articles in this issue
over 7 years ago
The Importance of Single-Use Components for Bioprocessingover 7 years ago
Buffers Benefit from Single-Use Systemsover 7 years ago
Thinking Flexibly in Biomanufacturingover 7 years ago
Single-Use Bioreactors Unwrap Commercial Manufacturing OptionsAdvertisement
Related to this article
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
Aptar Pharma's Nanopharm business will lead inhaled formulation development and device assessment for ACT-101, Aceso Therapeutics' antisense oligonucleotide candidate designed to correct CFTR protein function in cystic fibrosis patients carrying the F508del mutation.
Bristol Myers Squibb's GPRC5D-Directed CAR T Cell Therapy Meets Primary Endpoint in Multiple Myeloma
Bristol Myers Squibb reported positive topline phase 2 results for arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy, in patients with quadruple-class exposed relapsed and refractory multiple myeloma who had already received a prior BCMA-targeted therapy.
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Advertisement
Advertisement